Engineered immune cells take on Hard-to-Treat myeloma
NCT ID NCT07681596
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study tests a new treatment called AZD4045, which uses specially engineered immune cells (CAR-T cells) to target and kill multiple myeloma cells. The therapy is given alone or combined with other drugs (daratumumab and aldesleukin) in adults whose myeloma has returned or stopped responding to prior treatments. The goal is to see if it is safe and effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD4045 (allogeneic CAR-T cells targeting BCMA), daratumumab, aldesleukin
What this could lead to
If successful, this could offer a new treatment option for people with multiple myeloma that has stopped responding to standard therapies.
What could go wrong
This is an early-phase trial, so the treatment may not work or could cause serious side effects. The approach is complex and still experimental.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Home Carfilzomib for Myeloma: Pilot Study (NCT05041933)
- IBI3003 vs Standard Care for Multiple Myeloma (NCT07623798)
- UF-KURE-BCMA CAR T-Cell Trial for Multiple Myelo NCT07611149
- DQ1001 CAR-T for Multiple Myeloma Trial NCT07622862
- Elranatamab Outpatient Study for Multiple Myelom NCT07637578
- MMRC Horizon One Trial for Relapsed Myeloma (NCT06171685)
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
Duarte, California, 91010, United States
-
Research Site
Denver, Colorado, 80218, United States
-
Research Site
Tampa, Florida, 33612, United States
-
Research Site
Atlanta, Georgia, 30322, United States
-
Research Site
St Louis, Missouri, 63110, United States
-
Research Site
Hackensack, New Jersey, 07601, United States
-
Research Site
Cleveland, Ohio, 44195, United States
-
Research Site
Nashville, Tennessee, 37203, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Milwaukee, Wisconsin, 53226, United States
-
Research Site
Camperdown, 2050, Australia
-
Research Site
East Melbourne, 3002, Australia